Stocks of ImmunityBio Inc (NASDAQ:IBRX) traded higher last session on Wall Street, down -3.34% to $6.80.
IBRX stock price is now 7.22% away from the 50-day moving average and 73.91% away from the 200-day moving average. The market capitalization of the company currently stands at $4.71B.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
With the price target reduced from $10 to $4, Piper Sandler Downgraded its rating from Overweight to Neutral for ImmunityBio Inc (NASDAQ: IBRX). On August 03, 2022, Jefferies recently initiated its ‘Buy’ rating on the stock quoting a target price of $8
In other news, BLASZYK MICHAEL D, Director bought 71,915 shares of the company’s stock on Jun 05 ’23. The stock was bought for $198,023 at an average price of $2.75. Upon completion of the transaction, the Director now directly owns 71,915 shares in the company, valued at $0.49 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jun 02 ’23, Director Brennan John Owen bought 25,000 shares of the business’s stock. A total of $70,700 was incurred on buying the stock at an average price of $2.83. This leaves the insider owning 25,000 shares of the company worth $0.17 million. A total of 79.68% of the company’s stock is owned by insiders.
During the past 12 months, ImmunityBio Inc has had a low of $1.25 and a high of $10.53. The fifty day moving average price for IBRX is $6.3803 and a two-hundred day moving average price translates $3.936875 for the stock.
The latest earnings results from ImmunityBio Inc (NASDAQ: IBRX) was released for 2024-03-31. The company reported revenue of $40000.0 for the quarter, compared to $0.36 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -88.89 percent.
